Thank you for following Investing. You will receive email notifications for this source. To make changes to this, please visit your account.
You need to upgrade in order to follow more news source and receive email notifications about new articles and ratings, as your subscription allows only source. To change which news sources you follow, please visit your account.
C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development By Investing.com
The A.I. bias rating includes policy and politician portrayal leanings based on the author’s tone found in the article using machine learning. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral.
47% : For more information, visit c-path.org.Critical Path Institute is supported by the Food and Drug Administration (FDA) of the Department of Health and Human Services (HHS) and is 54% funded by the FDA/HHS, totaling $19,436,549, and 46% funded by non-government source(s), totaling $16,373,368.
*Our bias meter rating uses data science including sentiment analysis, machine learning and our proprietary algorithm for determining biases in news articles. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral. The rating is an independent analysis and is not affiliated nor sponsored by the news source or any other organization.
Investing